These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 32014255)
1. Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest. Cao W; Yang Q; Yuan Z; Li H; Wang W; Xiao X; Wang Z; Liang L; Zhou P; Liu J; Hu X; Zhang B Biochem Biophys Res Commun; 2020 Apr; 524(3):549-554. PubMed ID: 32014255 [TBL] [Abstract][Full Text] [Related]
2. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer. Chen Y; Zhou H; Yang S; Su D Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556 [TBL] [Abstract][Full Text] [Related]
3. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair. Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128 [TBL] [Abstract][Full Text] [Related]
4. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma. Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291 [TBL] [Abstract][Full Text] [Related]
5. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest. Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345 [TBL] [Abstract][Full Text] [Related]
6. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis. Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072 [TBL] [Abstract][Full Text] [Related]
7. Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299). Crescenzi E; Chiaviello A; Canti G; Reddi E; Veneziani BM; Palumbo G Mol Cancer Ther; 2006 Mar; 5(3):776-85. PubMed ID: 16546993 [TBL] [Abstract][Full Text] [Related]
8. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells. Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357 [TBL] [Abstract][Full Text] [Related]
10. Penfluridol: An antipsychotic agent suppresses lung cancer cell growth and metastasis by inducing G0/G1 arrest and apoptosis. Xue Q; Liu Z; Feng Z; Xu Y; Zuo W; Wang Q; Gao T; Zeng J; Hu X; Jia F; Zhu Y; Xia Y; Yu L Biomed Pharmacother; 2020 Jan; 121():109598. PubMed ID: 31733572 [TBL] [Abstract][Full Text] [Related]
11. Decreased drug resistance of bladder cancer using phytochemicals treatment. Cho CJ; Yu CP; Wu CL; Ho JY; Yang CW; Yu DS Kaohsiung J Med Sci; 2021 Feb; 37(2):128-135. PubMed ID: 33280258 [TBL] [Abstract][Full Text] [Related]
12. Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo. Pongking T; Thongpon P; Intuyod K; Klungsaeng S; Thanan R; Chaidee A; Charoenram N; Kongsintaweesuk S; Sakonsinsiri C; Vaeteewoottacharn K; Pinlaor S; Pinlaor P BMC Complement Med Ther; 2024 Aug; 24(1):325. PubMed ID: 39215312 [TBL] [Abstract][Full Text] [Related]
13. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway. Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285 [TBL] [Abstract][Full Text] [Related]
14. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway. Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550 [TBL] [Abstract][Full Text] [Related]
15. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles. Nascimento AV; Singh A; Bousbaa H; Ferreira D; Sarmento B; Amiji MM Acta Biomater; 2017 Jan; 47():71-80. PubMed ID: 27697601 [TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis in non-small lung carcinoma cell line (H1299) by combination of anti-asthma drugs with gemcitabine and cisplatin. Merimsky O; Hirsh L; Dantes A; Land-Bracha A; Suh BS; Amsterdam A Int J Oncol; 2005 Feb; 26(2):475-82. PubMed ID: 15645133 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo. Teng JP; Yang ZY; Zhu YM; Ni D; Zhu ZJ; Li XQ Eur Rev Med Pharmacol Sci; 2018 Jun; 22(12):3819-3825. PubMed ID: 29949158 [TBL] [Abstract][Full Text] [Related]
19. Long non‑coding RNA AK001796 contributes to cisplatin resistance of non‑small cell lung cancer. Liu B; Pan CF; Ma T; Wang J; Yao GL; Wei K; Chen YJ Mol Med Rep; 2017 Oct; 16(4):4107-4112. PubMed ID: 29067469 [TBL] [Abstract][Full Text] [Related]
20. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]